Health
Sanofi and GSK start Phase II study of their COVID-19 vaccine candidate – European Pharmaceutical Review
The dose finding study will assess the safety, reactogenicity and immunogenicity of the investigational COVID-19 vaccine in 720 participants.
Posted: 24 February 2021 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
The dose finding study will assess the safety, reactogenicity and immunogenicity of the companies investigational COVID-19 vaccine in 720 participants.
Sanofi and GlaxoSmithKline (GSK) have announced the initiation of a new Phase II study of their adjuvanted recombinant protein COVID-19 vaccine candidate.
The Phase II trial is a randomised, double-blind, multi-centre dose finding study and will evaluate…
Continue Reading
